Is LEGN or BNTX more profitable?

Legend Biotech has a net margin of -21.98% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% BioNTech -44.39% -5.30% -4.62%

Does the media prefer LEGN or BNTX?

In the previous week, Legend Biotech had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Legend Biotech and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.07 beat Legend Biotech's score of 0.14 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or LEGN?

In the previous week, Roivant Sciences had 4 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Roivant Sciences and 6 mentions for Legend Biotech. Roivant Sciences' average media sentiment score of 1.51 beat Legend Biotech's score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, INSM or LEGN?

Legend Biotech has higher revenue and earnings than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.25 -$1.28B -$5.75 N/A Legend Biotech $1.03B 5.30 -$296.80M -$0.68 N/A

Is INSM or LEGN more profitable?

Legend Biotech has a net margin of -21.98% compared to Insmed's net margin of -144.44%. Legend Biotech's return on equity of -24.92% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Legend Biotech -21.98% -24.92% -14.87%

Does the media prefer INSM or LEGN?

In the previous week, Insmed had 9 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Insmed and 6 mentions for Legend Biotech. Insmed's average media sentiment score of 1.45 beat Legend Biotech's score of 0.14 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 13 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LEGN or MRNA more profitable?

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Moderna -143.55% -26.64% -19.32%

Does the media prefer LEGN or MRNA?

In the previous week, Moderna had 43 more articles in the media than Legend Biotech. MarketBeat recorded 49 mentions for Moderna and 6 mentions for Legend Biotech. Moderna's average media sentiment score of 0.44 beat Legend Biotech's score of 0.14 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 22 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 12 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTRS or LEGN more profitable?

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Legend Biotech -21.98% -24.92% -14.87%

Does the media prefer VTRS or LEGN?

In the previous week, Legend Biotech had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.47 beat Legend Biotech's score of 0.14 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Legend Biotech (LEGN) Competitors

$29.34 +1.41 (+5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$29.29 -0.05 (-0.18%)

As of 06:21 PM Eastern

Compare

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

Should you buy Legend Biotech stock or one of its competitors? MarketBeat compares Legend Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Legend Biotech include BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Legend Biotech compare to BioNTech?

Legend Biotech (NASDAQ:LEGN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

In the previous week, Legend Biotech had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Legend Biotech and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.07 beat Legend Biotech's score of 0.14 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech presently has a consensus price target of $60.23, indicating a potential upside of 105.29%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 43.66%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has a net margin of -21.98% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
BioNTech	-44.39%	-5.30%	-4.62%

Legend Biotech has higher earnings, but lower revenue than BioNTech. Legend Biotech is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
BioNTech	$3.25B	7.03	-$1.29B	-$5.88	N/A

Summary

BioNTech beats Legend Biotech on 11 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Legend Biotech has a net margin of -21.98% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Legend Biotech	-21.98%	-24.92%	-14.87%

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential upside of 7.49%. Legend Biotech has a consensus target price of $60.23, indicating a potential upside of 105.29%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Roivant Sciences had 4 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Roivant Sciences and 6 mentions for Legend Biotech. Roivant Sciences' average media sentiment score of 1.51 beat Legend Biotech's score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Legend Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,721.21	-$299.77M	-$0.60	N/A
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A

Summary

Roivant Sciences and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Insmed had 9 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Insmed and 6 mentions for Legend Biotech. Insmed's average media sentiment score of 1.45 beat Legend Biotech's score of 0.14 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech has higher revenue and earnings than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.25	-$1.28B	-$5.75	N/A
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A

Insmed presently has a consensus price target of $211.86, indicating a potential upside of 114.85%. Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 105.29%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

70.9% of Legend Biotech shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Legend Biotech has a net margin of -21.98% compared to Insmed's net margin of -144.44%. Legend Biotech's return on equity of -24.92% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Insmed beats Legend Biotech on 10 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Moderna?

Legend Biotech (NASDAQ:LEGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Legend Biotech has higher earnings, but lower revenue than Moderna. Legend Biotech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
Moderna	$1.94B	12.11	-$2.82B	-$8.15	N/A

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Moderna	-143.55%	-26.64%	-19.32%

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

In the previous week, Moderna had 43 more articles in the media than Legend Biotech. MarketBeat recorded 49 mentions for Moderna and 6 mentions for Legend Biotech. Moderna's average media sentiment score of 0.44 beat Legend Biotech's score of 0.14 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	22 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech currently has a consensus target price of $60.23, indicating a potential upside of 105.29%. Moderna has a consensus target price of $36.60, indicating a potential downside of 38.33%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Legend Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Legend Biotech and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Viatris?

Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

In the previous week, Legend Biotech had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.47 beat Legend Biotech's score of 0.14 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Legend Biotech has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.25	-$3.51B	-$0.26	N/A
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 13.78%. Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 105.29%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Viatris beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.45B	$3.43B	$6.42B	$12.38B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-43.15	19.86	24.82	24.35
Price / Sales	5.30	330.21	571.82	128.85
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	5.40	8.34	10.85	6.58
Net Income	-$296.80M	$23.80M	$3.56B	$336.75M
7 Day Performance	-17.31%	3.63%	0.71%	-0.49%
1 Month Performance	-0.10%	1.77%	0.29%	1.56%
1 Year Performance	-13.71%	58.60%	30.68%	33.78%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	4.3908 of 5 stars	$29.34 +5.0%	$60.23 +105.3%	-17.9%	$5.45B	$1.03B	N/A	2,965
BNTX BioNTech	4.5557 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-14.7%	$22.90B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.1003 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+174.5%	$21.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.5017 of 5 stars	$97.46 -0.4%	$212.50 +118.0%	-6.8%	$21.21B	$606.42M	N/A	1,664	Positive News
MRNA Moderna	1.2371 of 5 stars	$52.13 +4.4%	$36.60 -29.8%	+146.9%	$19.80B	$1.94B	N/A	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

How does Legend Biotech compare to BioNTech?

Summary

How does Legend Biotech compare to Roivant Sciences?

Summary

How does Legend Biotech compare to Insmed?

Summary

How does Legend Biotech compare to Moderna?

Summary

How does Legend Biotech compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

How does Legend Biotech compare to BioNTech?

Which has more risk & volatility, LEGN or BNTX?

Does the media prefer LEGN or BNTX?

Do analysts rate LEGN or BNTX?

Do insiders and institutionals have more ownership in LEGN or BNTX?

Is LEGN or BNTX more profitable?

Which has stronger earnings & valuation, LEGN or BNTX?

Summary

How does Legend Biotech compare to Roivant Sciences?

Is ROIV or LEGN more profitable?

Do analysts recommend ROIV or LEGN?

Does the media favor ROIV or LEGN?

Which has more risk and volatility, ROIV or LEGN?

Do insiders & institutionals have more ownership in ROIV or LEGN?

Which has preferable valuation & earnings, ROIV or LEGN?

Summary

How does Legend Biotech compare to Insmed?

Does the media prefer INSM or LEGN?

Which has stronger valuation & earnings, INSM or LEGN?

Do analysts recommend INSM or LEGN?

Do insiders & institutionals have more ownership in INSM or LEGN?

Which has more risk and volatility, INSM or LEGN?

Is INSM or LEGN more profitable?

Summary

How does Legend Biotech compare to Moderna?

Which has better earnings and valuation, LEGN or MRNA?

Is LEGN or MRNA more profitable?

Which has more volatility & risk, LEGN or MRNA?

Does the media prefer LEGN or MRNA?

Do analysts recommend LEGN or MRNA?

Do insiders & institutionals have more ownership in LEGN or MRNA?

Summary

How does Legend Biotech compare to Viatris?

Does the media prefer VTRS or LEGN?

Do insiders & institutionals have more ownership in VTRS or LEGN?

Which has stronger earnings and valuation, VTRS or LEGN?

Do analysts prefer VTRS or LEGN?

Which has more volatility & risk, VTRS or LEGN?

Is VTRS or LEGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools